


# BARNES & THORNBURG

11 South Meridian Street  
Indianapolis, Indiana 46204  
(317) 236-1313  
(317) 231-7433 Fax

## ***IN THE UNITED STATES PATENT AND TRADEMARK OFFICE***

<i>Group:</i>	Unknown	}	<u>Certificate Under 37 CFR 1.10</u>
<i>Confirmation No.:</i>	Unknown	}	Express Mail Label No. <u>EV 337 241 498 US</u>
<i>Application No.:</i>	Unknown	}	Date of Deposit: <u>October 22, 2003</u>
<i>Invention:</i>	<b>Low Dose Interferon-Gamma Compositions And Their Use For Treatment Of Interferon-Sensitive Diseases e</b>	}	I hereby certify that this paper or fee is being deposited with the United States Postal Service's "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: The Commissioner for Patents, Alexandria, VA 22313- 1450, Mail Stop New Patent Application
<i>Applicant:</i>	Joseph M. Cummins et al.	}	<u>Garla L. Twyman</u> Typed or Printed Name of Person Mailing Paper or Fee
<i>Filed:</i>	Herewith (October 22, 2003)	}	 Signature of Person Mailing Paper or Fee
<i>Attorney Docket:</i>	5523-AMENTO	}	
<i>Examiner:</i>	Unknown	}	

### **INFORMATION DISCLOSURE STATEMENT**

Mail Stop New Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

This statement is filed in the application identified above pursuant to 37 C.F.R. § 1.97. No representation is intended that a complete search has been made of the prior art or that no better art references than listed below are available. The filing of this Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in §1.56(b).

Applicants believe that no fees are required for filing this statement. If any fees are required, the Assistant Commissioner is hereby authorized to charge the same to our Deposit Account No. 10-0435, with reference to our matter 5523-AMENTO. An extra copy of this Information Disclosure Statement is enclosed for that purpose.

Respectfully submitted,  
BARNES & THORNBURG

  
\_\_\_\_\_  
Rebecca L. Ball  
Reg. No. 46,535

Indianapolis, Indiana  
(317) 231-7511

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT				ATTY. DOCKET NO. 5523-AMENDO APPLICANT Joseph M. Cummins et al. FILING DATE Herewith (October 22, 2003)		SERIAL No. Unknown   GROUP Unknown	
U.S. PATENT DOCUMENTS							
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if
	AA	4,946,674	Aug. 7, 1990	von Eichborn et al.			
	AB	5,010,382	May 28, 1991	Cummins Jr.			
	AC	5,049,378	Sep. 17, 1991	Campos			
	AD	5,145,677	Sep. 8, 1992	von Eichborn et al.			
	AE	5,215,741	June 1, 1993	Young et al.			
	AF	5,248,499	Sep. 28, 1993	Czarniecki et al.			
	AG	5,830,456	Nov. 2, 1998	Cummins			
	AH	5,910,304	June 8, 1999	Cummins			
	AI	5,911,990	June 15, 1999	Marchalonis et al.			
	AJ	6,036,949	Mar. 14, 2000	Richards et al.			
	AK	5,178,857	Jan. 12, 1993	Goeth et al.			
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation Yes No
	AL	WO 97/41884	13 Nov 1997	PCT			
	AM	WO 97/41886	13 Nov 1997	PCT			
	AN	WP 99/44632	10 Sept. 1999	PCT			
	AO						
	AP						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AR	Tompkins, Wayne, "Immunomodulation and Therapeutic Effects of the Oral Use of Interferon- $\alpha$ : Mechanism of Action", <i>Journal of Interferon and Cytokine Research</i> , 19: 817-828 (1999)					
	AS	Cummins, Joseph et al., "Oral Use of Interferon", <i>Journal of Interferon and Cytokine Research</i> , 19: 853-857 (1999)					
	AT	Bocci, V., "The Oropharyngeal Delivery of Interferons: Where Are We and Where Do We Need to Go?", <i>Journal of Interferon and Cytokine Research</i> , 19: 859-861 (1999)					
	AU	Fleischmann, Jr., W. Robert, "Systemic Effects of Orally Administered Interferons and Interleukin-2", <i>Journal of Interferon and Cytokine Research</i> , 19: 829-839 (1999)					
	AV	Interferon Laboratories, "Interferon Nomenclature", <i>Journal of Interferon Research</i> , 1, pp. Vi (1980)					
	AW	Fleishmann, Jr., W. Robert, "Modulation of Peripheral Leukocyte Counts in Mice by Oral Administration of Interferons", <i>Oral Administration of IFN</i> , pp. 424-430 (1991)					
	AX	Tovey, Michael et al., "Oromucosal Interferon Therapy: Marked Antiviral and Antitumor Activity", <i>Journal of Interferon, and Cytokine Research</i> , 19: 145-155 (1999)					
	AY	Fleischmann Jr., W. Robert et al., "Orally Administered Interferons Exert Their White Blood Cell Suppressive Effects via a Novel Mechanism," <i>Proc. Soc. Exp. Biol. Med.</i> , 1992, 201 (12) 200-207.					
	AZ	Van Noort, J.M. et al., "Cell Biology of Autoimmune Diseases," <i>International Review of Cytology</i> , Vol. 178, (1998) 127-204					
Examiner						Date Considered	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

BASED ON FORM PTO 1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT				ATTY. DOCKET NO. 5523-AMENTO APPLICANT Joseph M. Cummins et al. FILING DATE Herewith (October 22, 2003)		SERIAL No. Unknown  GROUP Unknown	
U.S. PATENT DOCUMENTS							
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if
	BA	6,045,802	Apr. 4, 2000	Schlom et al.			
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation Yes No
	BL						
	BM						
	BN						
	BO						
	BP						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
	BR	Johansen, H.K. et al., "Interferon-gamma (IFN-gamma) Treatment Decreases the Inflammatory Response in Chronic Pseudomonas Aeruginosa Pneumonia in Rats," <i>Clinical and Experimental Immunology</i> , Vol. 103, No 2, 1996, 212-218.					
	BS	Cassatella, Marco A., "Interferon-Gamma Inhibits the Lipopolysaccharide-Induced Macrophage Inflammatory Protein-1 Alpha Gene Transcription In Human Neutrophils," <i>Immunology Letters</i> (1996), 49 (1,2), 79-82.					
	BT	Kox, Wolfgang J. et al., "Interferon Gamma-1b in the Treatment of Compensatory Anti-Inflammatory Response Syndrome: A New Approach: Proof of Principle," <i>Archives of Internal Medicine</i> , Vol. 157, No. 4, 1997, 389-393.					
	BU	Huang, T J et al., "Inhibitory Effects of Endogenous and Exogenous Interferon-Gamma on Bronchial Hyperresponsiveness, Allergic Inflammation and T-Helper 2-Cytokines in Brown-Norway Rats," <i>Immunology</i> , Vol. 98, No. 2, October 1999 (1999-10), 280-288					
	BV	Young, A.S. et al., "The History of Interferon and Its Use in Animal Therapy," <i>East African Medical Journal</i> , July 1990, 31-63					
	BW						
	BX						
	BY						
	BZ						
Examiner						Date Considered	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

BASED ON FORM PTO 1449